StockData
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. (CLRB) stock

CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.92−0.09 (-8.88%)

Close on Nov 17, 2026Market cap $8.70MP/E –Yield –

Cellectar Biosciences cash

Cash and short-term investments held at the end of each period.

Cellectar Biosciences's cash was $33.99M at Jun 30, 2026. For fiscal 2025 it was $13.20M, down 43.3% from the year before. Over ten years it grew 12.9% a year on average. The highest annual figure on record is $57.17M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.20M-43.3%
FY2024Dec 31, 2024$23.29M+143.5%
FY2023Dec 31, 2023$9.56M-51.9%
FY2022Dec 31, 2022$19.87M-44.4%
FY2021Dec 31, 2021$35.70M-37.5%
FY2020Dec 31, 2020$57.17M+438.5%
FY2019Dec 31, 2019$10.61M-20.3%
FY2018Dec 31, 2018$13.31M+32.3%
FY2017Dec 31, 2017$10.06M-12.5%
FY2016Dec 31, 2016$11.50M+193.9%
FY2015Dec 31, 2015$3.91M-58.5%
FY2014Dec 31, 2014$9.42M+289.6%
FY2013Dec 31, 2013$2.42M-48.3%
FY2012Dec 31, 2012$4.68M-15.0%
FY2011Dec 31, 2011$5.51M+717.2%
FY2010Dec 31, 2010$673.74K-31.3%
FY2009Dec 31, 2009$980.13K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$33.99M+207.9%
Q1 FY2026Mar 31, 2026$8.35M-40.0%
Q4 FY2025Dec 31, 2025$13.20M-43.3%
Q3 FY2025Sep 30, 2025$12.55M-63.4%
Q2 FY2025Jun 30, 2025$11.04M-57.3%
Q1 FY2025Mar 31, 2025$13.91M-65.3%
Q4 FY2024Dec 31, 2024$23.29M+143.5%
Q3 FY2024Sep 30, 2024$34.26M+80.5%
Q2 FY2024Jun 30, 2024$25.87M+402.0%
Q1 FY2024Mar 31, 2024$40.03M+215.6%
Q4 FY2023Dec 31, 2023$9.56M-51.9%
Q3 FY2023Sep 30, 2023$18.99M+6.8%
Q2 FY2023Jun 30, 2023$5.15M-79.2%
Q1 FY2023Mar 31, 2023$12.68M-58.6%
Q4 FY2022Dec 31, 2022$19.87M-44.4%
Q3 FY2022Sep 30, 2022$17.79M-55.9%
Q2 FY2022Jun 30, 2022$24.81M-47.0%
Q1 FY2022Mar 31, 2022$30.63M-42.9%
Q4 FY2021Dec 31, 2021$35.70M-37.5%
Q3 FY2021Sep 30, 2021$40.34M+114.1%
Q2 FY2021Jun 30, 2021$46.78M+108.4%
Q1 FY2021Mar 31, 2021$53.63M+656.1%
Q4 FY2020Dec 31, 2020$57.17M+438.5%
Q3 FY2020Sep 30, 2020$18.84M+41.7%
Q2 FY2020Jun 30, 2020$22.45M+33.2%
Q1 FY2020Mar 31, 2020$7.09M-32.4%
Q4 FY2019Dec 31, 2019$10.61M-20.3%
Q3 FY2019Sep 30, 2019$13.30M-19.0%
Q2 FY2019Jun 30, 2019$16.85M+297.8%
Q1 FY2019Mar 31, 2019$10.49M+52.6%
Q4 FY2018Dec 31, 2018$13.31M+32.3%
Q3 FY2018Sep 30, 2018$16.43M+187.4%
Q2 FY2018Jun 30, 2018$4.24M-49.4%
Q1 FY2018Mar 31, 2018$6.88M-38.8%
Q4 FY2017Dec 31, 2017$10.06M-12.5%
Q3 FY2017Sep 30, 2017$5.72M+1.3%
Q2 FY2017Jun 30, 2017$8.37M–
Q1 FY2017Mar 31, 2017$11.24M–
Q4 FY2016Dec 31, 2016$11.50M–
Q3 FY2016Sep 30, 2016$5.65M–

More Cellectar Biosciences figures

See a number that looks wrong?